Nutriband Inc. (NASDAQ: NTRB) announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office to strengthen intellectual property protection for its AVERSA abuse-deterrent transdermal technology. The application covers improved aversive formulations and coating methods designed to enhance the technology's abuse-deterrent properties. If granted, the patent could extend protection for AVERSA-based products, including AVERSA FENTANYL, through 2046. Nutriband currently holds patents in 46 countries covering its technology, which incorporates aversive agents into transdermal patches to help prevent abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulants.
The filing represents a significant step for Nutriband, which is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company's lead product under development is an abuse-deterrent fentanyl patch incorporating its AVERSA abuse-deterrent technology. According to the company, AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. This broad applicability positions Nutriband to potentially address a wide range of drugs beyond opioids, including stimulants, which are also prone to abuse.
The importance of this development lies in its potential to extend market exclusivity for AVERSA-based products. If the patent is granted, Nutriband could benefit from protection through 2046, providing a longer window to commercialize its technology without generic competition. This could be particularly valuable for AVERSA FENTANYL, which, if approved, would be the first abuse-deterrent fentanyl patch. The global opioid crisis has heightened the need for such technologies, and a longer patent life could incentivize further investment in research and development.
For investors, the patent application signals Nutriband's commitment to protecting its intellectual property and building a robust portfolio. The company's existing patents in 46 countries demonstrate a global strategy to safeguard its technology. The latest application, if successful, would add another layer of protection, potentially increasing the value of the company's assets and making it a more attractive partner for pharmaceutical companies seeking to develop abuse-deterrent products.
To view the full press release, visit https://ibn.fm/Osmxh. The latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. Nutriband's website is www.nutriband.com. Any material contained in or derived from the company's websites or any other website is not part of this press release.
MissionIR, a specialized communications platform, distributed the announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, among other services. The platform provides editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit MissionIR. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
